Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12614000148673
Ethics application status
Approved
Date submitted
27/01/2014
Date registered
6/02/2014
Date last updated
6/02/2014
Type of registration
Retrospectively registered
Titles & IDs
Public title
Effect of metformin and diet in treatment of metabolic syndrome
Query!
Scientific title
Comparison of the effect of low glycemic index diet and metformin drug on metabolic syndrome components in adults with metabolic syndrome.
Query!
Secondary ID [1]
282653
0
none
Query!
Universal Trial Number (UTN)
U1111-1144-2404
Query!
Trial acronym
-
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
metabolic syndrome
290222
0
Query!
Condition category
Condition code
Diet and Nutrition
290614
290614
0
0
Query!
Other diet and nutrition disorders
Query!
Metabolic and Endocrine
291407
291407
0
0
Query!
Metabolic disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
The 60 patients will randomly allocated to two group of metformin drug and lowGI diet. The dose of administration for the metformin group will be 500mg (1 oral tab daily) for 8 weeks.
For the diet group the percentage of requiered energy will be calculated with harris-benedict formula.The percentage of macronutrients are the same for all participants and will be 50% carbohydrate,30%fat and 20%protein.The only difference to normal diet is the use of low-GI foods in the diet plan. The foods will be chosen from Foster-Powel Table ,will medium (55-70) and low(less than 55) glycemic index.
we will make a phone call in every 2weeks for monitoring the patients. The intervention period for both groups is 8 weeks.
Query!
Intervention code [1]
288054
0
Lifestyle
Query!
Intervention code [2]
288710
0
Treatment: Drugs
Query!
Comparator / control treatment
The 60 patients will randomly allocated to two group of metformin drug and lowGI diet. there is no control group but the diet group can be consider as comparator group.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
290683
0
weight
method of measurement: seca scale
Query!
Assessment method [1]
290683
0
Query!
Timepoint [1]
290683
0
8 weeks
Query!
Primary outcome [2]
291399
0
lipid profil(TG,HDL,LDL,total Chol)
method of measurement: biosystem autoanalyzer bt1500
Query!
Assessment method [2]
291399
0
Query!
Timepoint [2]
291399
0
8weeks
Query!
Primary outcome [3]
291400
0
fasting blood sugre
method of measurement: biosystem autoanalyzer bt1500
Query!
Assessment method [3]
291400
0
Query!
Timepoint [3]
291400
0
8 weeks
Query!
Secondary outcome [1]
306580
0
none
Query!
Assessment method [1]
306580
0
Query!
Timepoint [1]
306580
0
none
Query!
Eligibility
Key inclusion criteria
Having 3 characteristics related to metabolic syndrome according to the Adult Treatment Panel, Not taking any drug that might affect blood pressure and glucose , insulin or lipid metabolism , Not having diabetes, liver or kidney diseases.
Query!
Minimum age
25
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Patients will excluded if they get gastrointestinal disorders or not willing to continue the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The 60 patients will randomly allocated to two group of metformin drug and lowGI diet . As the patients register for entering the trial one of them goes to diet group and the other goes to metformin group respectively. The method of allocation concealment is numbered containers.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
simple randomisation using drawing
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
the number of participants calculated with the related formula with these assumptions:d =8 s=10
Z 1-alph/2=1.96 Z1-beta =0.89
methods of analysis:
independent T test
Mann- whitney U test
kolomogrov-smirnov or shapiro
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
24/08/2013
Query!
Actual
24/08/2013
Query!
Date of last participant enrolment
Anticipated
19/02/2014
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
60
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
5776
0
Iran, Islamic Republic Of
Query!
State/province [1]
5776
0
shiraz
Query!
Funding & Sponsors
Funding source category [1]
288609
0
University
Query!
Name [1]
288609
0
Shiraz University of Medical Sciences
Query!
Address [1]
288609
0
Shiraz University of Medical Sciences building, front of Felestin St. Zand St. Shiraz, Fars, Iran, Islamic Republic Of.
PostCode:14336 - 71348
Query!
Country [1]
288609
0
Iran, Islamic Republic Of
Query!
Primary sponsor type
University
Query!
Name
Vice-Chancellery of Research and Technology, Shiraz University of Medical Sciences
Query!
Address
Vice-Chancellery of Research and Technology,store 7th, Shiraz University of Medical Science Centeral Bulding, beside Helale-Ahmar, Zand Street,Shiraz,Fars,Iran.
postcode:14336 - 71348.
Query!
Country
Iran, Islamic Republic Of
Query!
Secondary sponsor category [1]
287319
0
None
Query!
Name [1]
287319
0
Query!
Address [1]
287319
0
Query!
Country [1]
287319
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
290471
0
Ethics Committee of Shiraz University of Medical Sciences
Query!
Ethics committee address [1]
290471
0
Zand St. Shiraz, Fars. post code:14336 - 71348
Query!
Ethics committee country [1]
290471
0
Iran, Islamic Republic Of
Query!
Date submitted for ethics approval [1]
290471
0
04/08/2013
Query!
Approval date [1]
290471
0
19/08/2013
Query!
Ethics approval number [1]
290471
0
CT-92-6678
Query!
Summary
Brief summary
Metabolic syndrome continues to be highly prevalent and contributes to a rapidly growing problem globally. The most important therapeutic intervention, that its efficacy in metabolic syndrome has been proven, is diet modification. A number of studies have shown that low glycemic index diet have positive effects on patients with MetS . So the goal of this study is to compare the effects of low Glycemic Index diet and metformin drug on MetS components in order to replace the drug by the diet in adults with MetS. This study is a Randomised Clinical Controlled Trial. The including criteria is the age between 25 to 65 years old and having 3 characteristics related to metabolic syndrome according to the Adult Treatment Panel, Not taking any drug that might affect blood pressure and glucose , insulin or lipid metabolism , Not having diabetes, liver or kidney diseases . Patients will be excluded if they get gastrointestinal disorders or not willing to continue the study. The 60 patients will randomly allocated to two group of metformin drug and lowGlycemic Index diet. The intervention period is 8 weeks and at the end of the trial groups will be compared for the following factors: weight , blood pressure , waist circumference, fasting blood sugar and lipid profiles (TG, total cholesterol, LDL, HDL).
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
40670
0
A/Prof dr zohre mazlom
Query!
Address
40670
0
shiraz university of medical sciences-nutrition faculty--front of bargh stadium- koye zahra blvd-shiraz-Fars-Iran
post code:75541-71536
Query!
Country
40670
0
Iran, Islamic Republic Of
Query!
Phone
40670
0
+987117251001
Query!
Fax
40670
0
Query!
Email
40670
0
[email protected]
Query!
Contact person for public queries
Name
40671
0
dr zohre mazlom
Query!
Address
40671
0
dr zohre mazlom-shiraz university of medical sciences-nutrition faculty--front of bargh stadium- koye zahra blvd-shiraz-Fars-Iran
post code:75541-71536
Query!
Country
40671
0
Iran, Islamic Republic Of
Query!
Phone
40671
0
+987117251001
Query!
Fax
40671
0
Query!
Email
40671
0
[email protected]
Query!
Contact person for scientific queries
Name
40672
0
dr zohre mazlom
Query!
Address
40672
0
shiraz university of medical sciences-nutrition faculty--front of bargh stadium- koye zahra blvd-shiraz-Fars-Iran
post code:75541-71536
Query!
Country
40672
0
Iran, Islamic Republic Of
Query!
Phone
40672
0
+987117251001
Query!
Fax
40672
0
Query!
Email
40672
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF